First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

Balton

Status: Completed

Conditions: Femoropopliteal Artery Disease; Peripheral Artery Disease

Treatments: Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland); Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02145065

PAX-0314

Details and patient eligibility

About

The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.

Full description

Although clinically effective, the manufacturing process of first generation PCB coatings contributed to inconsistent drug concentrations, particulate formations on the balloon surface and their shedding during the interventional procedures. As a consequence developments of new PCB coatings have been proposed to address consistency, uniformity, small particle drug coverage, which may potentially contribute to improved vessel healing profile and improved clinical outcomes. Nevertheless, data on the safety and efficacy of this novel coating developments in the clinical setting remain limited. Previously in the experimental model, the investigators reported that delivery of paclitaxel via a novel mcPCB resulted in low long-term tissue retention of paclitaxel, however displayed reduced neointimal proliferation and favorable healing profile. Therefore in current clinical trial the investigators will address the feasibility and safety of the mcPCB (PAK, Balton) in the treatment of femoropopliteal restenotic disease in a prospective, randomized manner when compared to plain balloon angioplasty (PBA). The efficacy analysis will be observational and evaluated post-hoc, with no prespecified criteria.

Enrollment: 66 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 y.o.
• Claudication in Rutherford Class 1-5,
• Lesion in the femoropopliteal artery defined as >50% and < 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm
• Chronic total occlusions of length less than 100 mm
• Ability to cross the lesions with a guidewire.

Exclusion criteria

• Critical acute or chronic limb ischemia
• Acute coronary syndrome
• Chronic kidney disease stage III-V
• Restenotic lesion
• Femoropopliteal graft
• Known allergy to clopidogrel or aspirin
• History of stroke within past 6 months
• Age > 80 y.o.
• Life expectancy < 2 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

66 participants in 2 patient groups

Plain Balloon Angioplasty

Active Comparator group

Description:

Plain Balloon Angioplasty

Treatment:

Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)

microcrystalline Paclitaxel Coated Balloon (PAK)

Experimental group

Description:

plain balloon angioplasty followed by mcPCB dilation

Treatment:

Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)